Alachua, FL (PRWEB) September 06, 2012
AxoGen, Inc. (OTCBB: AXGN) announced today that it has launched an initiative to support wounded warriors with the “Thank a Wounded Warrior” program at the American Society for Surgery of the Hand 2012 Meeting, September 6-8, in Chicago. Participants attending ASSH are invited to join AxoGen employees in Booth 1112 and sign Thank You cards for US military personnel injured in service to our Country.
On Saturday, September 8, all signed cards will be presented to Patricia L. McKay MD, CAPT, MC, USN, Deputy Chair, Uniformed Services, University of the Health Sciences, Hand and Upper Extremity Surgery, Walter Reed National Military Medical Center for immediate distribution to wounded military personnel currently hospitalized at Walter Reed National Military Medical Center.
In addition, AxoGen has partnered with the Wounded Warrior Project for this event and will make a donation to the charity to facilitate the rehabilitation and recovery of injured military personnel. The Company will also accept additional contributions from ASSH Attendees on behalf of Wounded Warrior Project.
“Military injuries frequently involved damage to peripheral nerves in the upper and lower extremities. Our technologies provide repair options for surgeons and patients, especially when a sufficient quantity of autologous nerve material is not available,” said Jill Schiaparelli, Senior Vice President, Business Strategy & Marketing. “We have been humbled by amazing stories of rehabilitation and recovery of patients and have chosen to recognize the extraordinary sacrifice of these fine men and women by creating “Thank a Wounded Warrior.”
AxoGen’s portfolio of surgical products is used to repair and reconstruct injured and severed peripheral nerves and includes Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging nerve discontinuities of 5mm to 70mm in length, AxoGuard® Nerve Connector, and AxoGuard® Nerve Protector.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science of peripheral nerve repair and commercializing next generation surgical technologies. The Company’s portfolio of proprietary products and technologies offers new options for surgical nerve repair and reconstruction. Every day, people suffer traumatic injuries and damage caused by disease and prior surgery that impacts the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only commercially available process nerve allograft nerve for bridging nerve discontinuities of 5mm to 70mm in length, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves gaps up to 5mm in length, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.
AxoGen brings the science of nerve repair to life with thousands of surgical implants of AxoGen products and technology performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.
“Thank a Wounded Warrior” is sponsored by AxoGen, Inc. which is solely responsible for its fulfillment. The Wounded Warrior Project will receive a donation of at least $5,000 following ASSH 2012 and its name and logo are used by permission. More information about the Wounded Warrior Project can be found at http://www.woundedwarriorproject.org or by calling WWP at 877.832.6997.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html .
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.